- Home
- REGN vs APP Comparison
REGN vs APP Comparison
Compare REGN & APP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- APP
- Stock Information
- Founded
- REGN 1988
- APP 2012
- Country
- REGN United States
- APP United States
- Employees
- REGN N/A
- APP N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- APP EDP Services
- Sector
- REGN Health Care
- APP Technology
- Exchange
- REGN Nasdaq
- APP Nasdaq
- Market Cap
- REGN 110.0B
- APP 116.4B
- IPO Year
- REGN 1991
- APP 2021
- Fundamental
- Price
- REGN $681.58
- APP $342.34
- Analyst Decision
- REGN Buy
- APP Buy
- Analyst Count
- REGN 25
- APP 20
- Target Price
- REGN $1,024.28
- APP $304.89
- AVG Volume (30 Days)
- REGN 857.0K
- APP 4.0M
- Earning Date
- REGN 02-04-2025
- APP 02-12-2025
- Dividend Yield
- REGN N/A
- APP N/A
- EPS Growth
- REGN 15.31
- APP 1098.41
- EPS
- REGN 40.43
- APP 3.31
- Revenue
- REGN $13,847,100,000.00
- APP $4,289,729,999.00
- Revenue This Year
- REGN $10.24
- APP $41.33
- Revenue Next Year
- REGN $4.30
- APP $22.48
- P/E Ratio
- REGN $16.86
- APP $103.48
- Revenue Growth
- REGN 5.72
- APP 41.48
- 52 Week Low
- REGN $666.25
- APP $40.71
- 52 Week High
- REGN $1,211.20
- APP $417.64
- Technical
- Relative Strength Index (RSI)
- REGN 36.27
- APP 55.37
- Support Level
- REGN $666.25
- APP $307.07
- Resistance Level
- REGN $743.28
- APP $362.45
- Average True Range (ATR)
- REGN 19.76
- APP 16.82
- MACD
- REGN 0.45
- APP -2.16
- Stochastic Oscillator
- REGN 19.90
- APP 63.69
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
About APP Applovin Corporation
AppLovin Corp is a mobile app technology company. It focuses on growing the mobile app ecosystem by enabling the success of mobile app developers. The company's software solutions provide tools for mobile app developers to grow their businesses by automating and optimizing the marketing and monetization of their applications.